Clinical Trials Logo

Clinical Trial Summary

Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Interferon-based immunomodulatory therapies are effective in blocking the production of cytokines in the Th17 pathway avoiding an increased risk of infection, unlike immunosuppressive treatments. To date, these treatments have not been evaluated in the management of MN. The aims of the ALPHAGEM project are to monitor the immunological activity of the disease before and after 6 months of personalized interferon-alfa treatment in MN patients.


Clinical Trial Description

Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies, in particular the anti-phospholipase A2 receptor antibodies (anti-PLA2R1). The development of these autoantibodies is the consequence of a genetic predisposition, environmental factors and a dysregulation of the immune response, with increased production of pro-inflammatory Th2 and Th17 cytokines. Current management is based on the use of immunosuppressive therapies to induce immunological remission, which precedes clinical remission. Disease relapse may occur in 5-28% of patients, and may be complicated by long-term renal failure. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Rituximab induces the regulatory T pathway, but has no impact on the Th17 pathway. Interferon-based immunomodulatory therapies are effective in blocking the production of cytokines in the Th17 pathway avoiding an increased risk of infection, unlike immunosuppressive treatments. These treatments have been used for many years in the management of autoimmune diseases (such as multiple sclerosis for interferon beta) and viral infectious diseases (such as chronic hepatitis B for interferon alfa), affections where the Th17 pathway plays a key pathophysiological role. To date, these treatments have not been evaluated in the management of MN. The aims of the ALPHAGEM project are to monitor the immunological activity of the disease before and after 6 months of personalized interferon-alfa treatment in MN patients with immunological relapse and a Th17-type cytokine profile, and to assess drug tolerance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05941845
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Maxime TEISSEYRE, MD
Phone +33492038828
Email teisseyre.m@chu-nice.fr
Status Not yet recruiting
Phase Phase 2
Start date July 24, 2023
Completion date July 24, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04095156 - Autoreactive B Cells in Membranous Nephropathy
Not yet recruiting NCT06341205 - Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) Phase 3
Active, not recruiting NCT04893096 - MOR202 for Refractory MN Phase 2
Completed NCT00405340 - Rituximab in the Treatment of Idiopathic Membranous Nephropathy Phase 0
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Active, not recruiting NCT04652570 - Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy Phase 1/Phase 2
Not yet recruiting NCT06242327 - An Outcome Analysis of Primary Membranous Nephropathy
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting NCT03949855 - Belimumab With Rituximab for Primary Membranous Nephropathy Phase 2
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT03025828 - Adrenocorticotropic Hormone in Membranous Nephropathy Phase 4
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Active, not recruiting NCT05894512 - Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Completed NCT00518219 - To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Phase 4
Completed NCT02199145 - Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy N/A
Not yet recruiting NCT04326218 - Immunopathological Analysis in a French National Cohort of Membranous Nephropathy N/A
Active, not recruiting NCT03453619 - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Phase 2
Completed NCT01955187 - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Phase 3
Completed NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) Phase 2